Get the Stockscreener App
6.80
1.95%
0.13
After Hours:
6.93
0.13
+1.91%
Lexeo Therapeutics Inc stock is traded at $6.80, with a volume of 608.61K.
It is up +1.95% in the last 24 hours and up +2.10% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
See More
Previous Close:
$6.67
Open:
$6.65
24h Volume:
608.61K
Relative Volume:
0.59
Market Cap:
$503.79M
Revenue:
$531.00K
Net Income/Loss:
$-99.96M
P/E Ratio:
-3.1023
EPS:
-2.1919
Net Cash Flow:
$-98.96M
1W Performance:
+5.59%
1M Performance:
+2.10%
6M Performance:
-22.99%
1Y Performance:
+166.67%
1-Day Range:
$6.425
$6.825
1-Week Range:
$5.93
$6.88
52-Week Range:
$2.19
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
6.80 | 494.16M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Raymond James | Strong Buy |
| Nov-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-15-25 | Initiated | Guggenheim | Buy |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Suvretta, Averill disclose multi-million share holdings in Lexeo Therapeutics (NASDAQ: LXEO) - Stock Titan
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Layoff Watch: Is Lexeo Therapeutics Inc backed by strong institutional buying2026 Big Picture & Expert Curated Trade Setup Alerts - baoquankhu1.vn
CEO Change: Is Lexeo Therapeutics Inc attractive for institutional investors2026 Intraday Action & Accurate Intraday Trade Tips - baoquankhu1.vn
Insiders In Lexeo Therapeutics Left Out From 14% Price Rise After Disposing Stock - simplywall.st
Insider Sell: Richard Townsend Sells 55,000 Shares of Lexeo Ther - GuruFocus
Lexeo Therapeutics CEO Townsend sells $313k in shares By Investing.com - Investing.com Canada
Lexeo (LXEO) CEO sells 55,000 shares, keeps 340K including RSUs - Stock Titan
[144] Lexeo Therapeutics, Inc. SEC Filing - Stock Titan
If You Invested $1,000 in Lexeo Therapeutics Inc (LXEO) - Stock Titan
Lexeo Therapeutics (LXEO) Price Target Increased by 19.77% to 21.29 - MSN
LXEO Technical Analysis & Stock Price Forecast - intellectia.ai
Published on: 2026-04-02 23:43:24 - baoquankhu1.vn
LXEO Earnings History & Surprises | EPS & Revenue Results | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Oppenheimer Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail
Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely? - Yahoo Finance
Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Lexeo Therapeutics stock Overweight rating - Investing.com
Lexeo Therapeutics 2025 Annual Report: Advancing Genetic Medicine for Cardiovascular Diseases - Minichart
Big Picture: Should I invest in Lexeo Therapeutics Inc before earnings2026 AllTime Highs & Verified High Yield Trade Plans - baoquankhu1.vn
Lexeo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances - TipRanks
Lexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results - MarketBeat
Lexeo Therapeutics | 10-K: Annual report - Moomoo
Gene therapy advances at Lexeo Therapeutics (NASDAQ: LXEO) target heart disease - Stock Titan
Lexeo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Runway into 2028 as Lexeo (NASDAQ: LXEO) pushes pivotal cardiac gene therapies - Stock Titan
Lexeo Therapeutics : Corporate Presentation March 2026 - marketscreener.com
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - ChartMill
US Market Wrap: Is Lexeo Therapeutics Inc on track to beat earnings2026 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Vanguard realignment leads to separate LXEO holdings reporting (LXEO) - Stock Titan
Aug Mood: Will Lexeo Therapeutics Inc outperform its industry peers2026 Action & Capital Efficient Trading Techniques - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Gets a PT Cut to $13 by H.C. Wainwright Due to Equity Raise - MSN
Wall Street Recap: Is Lexeo Therapeutics Inc. subject to activist investor interestTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Hedge Fund Moves: Does Lexeo Therapeutics Inc have declining or rising EPSMarket Growth Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Published on: 2026-03-22 00:04:32 - baoquankhu1.vn
Oppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform Recommendation - msn.com
Is Lexeo Therapeutics Inc forming a bullish divergence2026 EndofYear Setup & Daily Profit Focused Screening - baoquankhu1.vn
Lexeo Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Lexeo Therapeutics (LXEO) CEO acquires 2,623 shares via employee stock plan - Stock Titan
Signal Recap: Can Lexeo Therapeutics Inc ride the EV waveMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Lexeo Therapeutics (LXEO) Projected to Post Earnings on Monday - MarketBeat
Rare disease spotlight: Friedreich ataxia moves beyond mitochondrial bandages - biocentury.com
LEXEO THERAPEUTICS Q4 2025 Earnings Preview: Recent $LXEO Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
LXEO: Pivotal studies for FA and PKP2 advance with strong clinical data, robust manufacturing, and solid financials - TradingView — Track All Markets
Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 10.4%What's Next? - MarketBeat
Sectors Review: Is Lexeo Therapeutics Inc. subject to activist investor interestWeekly Trade Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Is Lexeo Therapeutics Inc a cyclical or defensive stockMarket Volume Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):